Diabetes mellitus type 1 and coronary artery disease with severe systolic heart failure in 25 year-old adult

Diabetes mellitus (DM) type 1 accounts for up to 90% of all cases of diabetes among children, adolescents and young adults (10 % are represented by T2DM, MODY, etc.). DM is characterized not only by glucose metabolism disorder, but also by abnormal protein and lipid metabolism, leading to severe macrovascular complications. A clinical case of diabetes type 1, hyperlipidemia, coronary artery disease (CAD) and chronic heart failure (HF) in a 25-year-old adult has been demonstrated. The medical examination revealed lipid metabolism disorders, multivessel coronary artery disease, which required myocardial revascularization, and severe heart failure with a reduced ejection fraction (HFrEF). The clinical case demonstrates that proper cardiovascular examination should be performed in all patients with diabetes and lipid disorders, regardless of age and type of diabetes. The authors also consider the use of sodium-glucose 

1. Peterkova VA, Shestakova MV, Bezlepkina OB, et al. Diabetes mellitus type 1 in childhood. Diabetes mellitus. 2020;23(1S):4-40. (In Russ.). doi: https://doi.org/10.14341/DM12504

2. Homma TK, Endo CM, Saruhashi T, et al. Dyslipidemia in young patients with type 1 diabetes mellitus. Arch Endocrinol Metab. 2015;59(3):215-219. doi: https://doi.org/10.1590/2359-3997000000040

3. Mostofizadeh N, Hashemipour M, Roostazadeh M et al. The impact of poor glycemic control on lipid profile variables in children with type 1 diabetes mellitus. J Educ Health Promot. 2019;8:6. doi: https://doi.org/10.4103/jehp.jehp_194_17

4. Swasey KK, Orchard TJ, Costacou T. Trends in cardiovascular risk factor management in type 1 diabetes by sex. J Diabetes Complications. 2018;32(4):411-417. doi: https://doi.org/10.1016/j.jdiacomp.2018.01.003

5. Htay T, Soe K, Lopez-Perez A, et al. Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. Curr Cardiol Rep. 2019;21(6):45. doi: https://doi.org/10.1007/s11886-019-1133-9

6. Cai X, Li J, Cai W, et al. Meta-analysis of type 1 diabetes mellitus and risk of cardiovascular disease. J Diabetes Complications. 2021;35(4):107833. doi: https://doi.org/10.1016/j.jdiacomp.2020.107833

7. Dillmann WH. Diabetic Cardiomyopathy. Circ Res. 2019;124(8):1160-1162. doi: https://doi.org/10.1161/CIRCRESAHA.118.314665

8. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk [published correction appears in Eur Heart J. 2020;41(44):4255]. Eur Heart J. 2020;41(1):111-188. doi: https://doi.org/10.1093/eurheartj/ehz455

9. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-3337. doi: https://doi.org/10.1093/eurheartj/ehab484

10. Ezhov MV, Bazhan SS, Ershova AI, et al. Clinical guidelines for familial hypercholesterolemia. Ateroscleroz. 2019;15(1):58-98. (In Russ.).

11. Snaith JR, Holmes-Walker DJ, Greenfield JR. Reducing type 1 diabetes mortality: Role for adjunctive therapies? Trends Endocrinol Metab. 2020;31(2):150-164. doi: https://doi.org/10.1016/j.tem.2019.11.007

12. Holt RIG, DeVries JH, Hess-Fischl A, et al. The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2021;64(12):2609-2652. doi: https://doi.org/10.1007/s00125-021-05568-3

13. Danne T, Garg S, Peters AL, et al. International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with Sodium-Glucose Cotransporter (SGLT) Inhibitors. Diabetes Care. 2019;42(6):1147-1154. doi: https://doi.org/10.2337/dc18-2316

14. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure [published correction appears in Eur Heart J. 2021 Oct 14;]. Eur Heart J. 2021;42(36):3599-3726. doi: https://doi.org/10.1093/eurheartj/ehab368

15. Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N Engl J Med. 2021;384(2):117-128. doi: https://doi.org/10.1056/NEJMoa2030183

16. Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. N Engl J Med. 2021;384(2):129-139. doi: https://doi.org/10.1056/NEJMoa2030186